Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

Researchers sought to determine 1-year outcomes in patients being treated with tirzepatide who have atrial fibrillation.

Compounded tirzepatide contains the same active ingredient as Mounjaro, but its dosage and some ingredients may differ from Mounjaro. The Food and Drug Administration (FDA) does not regulate the ...

There are improved all-cause mortality, rhythm control, and adverse cardiac event outcomes in patients being treated with tirzepatide who have atrial fibrillation. Patients with atrial ...

Despite promising adherence and persistence data, tirzepatide dose escalation was slower in the real-world than clinical trials in patients with obesity without T2D. Tirzepatide dose escalation is ...

Semaglutide and tirzepatide prescriptions for obesity are influenced by race, gender, social vulnerability, and urbanicity, with disparities in access and utilization. Despite increased ...

A recent analysis of the SURPASS-3 trial unravels the impact of treatment with the drug tirzepatide on muscle volume and fat infiltration in individuals with type 2 diabetes. Published in The ...

Tirzepatide's uptake was rapid post-launch, surpassing other GLP-1 RAs and SGLT2 inhibitors, while conventional GLMs like metformin and insulin declined. The approval of tirzepatide for type 2 ...

Each participant received weekly doses of tirzepatide—either 5 mg, 10 mg, or 15 mg—for three years. At the end of this period, the results were impressive. On average, participants lost ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years in adults with overweight or obesity who do not have diabetes ...

Now, there may be another option for him. It's a drug called tirzepatide, also known as Mounjaro or Zepbound. It's FDA approved to manage diabetes and obesity. Now, UC San Diego researchers have ...

Late last year, the FDA approved tirzepatide (Zepbound, Eli Lilly) for adults with moderate to severe obstructive sleep apnea and obesity after the medication showed significantly more efficacy vs.